Align Technology, Inc. (NASDAQ: ALGN) is a Healthcare company (Medical - Devices) with a market capitalization of $11.5B. The Maz Rating grades it against the other companies in its sector.
Align Technology, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $163.46, Align Technology, Inc. trades at 23.7x trailing earnings, 2.8x sales and 2.7x book value, with an EV/EBITDA of 14.1. Over the last twelve months it generated about $4.2B of revenue and $486M of net income. It runs a gross margin of 67.6%, an operating margin of 15.0% and a net margin of 11.8%. It shows return on equity of 11.8%, return on invested capital of 10.3% and a free cash flow yield of 5.2%. On the balance sheet: a debt-to-equity ratio of 0.03 and a current ratio of 1.42. Over the past 52 weeks the share price ranged from $130.23 to $200.44, with a beta of 1.74.
Align Technology, Inc. does not currently pay a dividend.
33 Wall Street analyst ratings cover the stock: 22 Buy, 9 Hold and 2 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Align Technology, Inc. is a medical technology enterprise that develops, produces, and markets its leading products: Invisalign transparent dental aligners and iTero digital intraoral scanners, along with related services. These offerings serve a wide range of dental professionals, including orthodontists, general dentists, and those specializing in restorative and cosmetic dentistry. The company's operations are divided into two main business units: "Clear Aligner" and "Scanners and Services." The Clear Aligner segment offers a variety of solutions. Its comprehensive products include the full Invisalign treatment for teenage patients, designed to address complex orthodontic needs such as mandibular advancement, patient compliance tracking, and managing tooth eruption. It also features specialized Invisalign First Phase I and Phase 2 packages for younger children, typically aged seven to ten, who have mixed dentition (a combination of primary and permanent teeth). Beyond these, the segment provides non-comprehensive aligner options like Invisalign moderate, lite, express, and Invisalign Go. Additional non-case products include retention devices, fees for Invisalign training, and sales of ancillary items such as cleaning materials and adjustment tools used by dental practitioners during treatment. The Scanners and Services segment centers around the iTero scanner, a unified hardware platform offering various software applications for both restorative and orthodontic procedures. It supplies specialized restorative software to general dentists, prosthodontists, periodontists, and oral surgeons, as well as distinct software for orthodontists to manage digital patient records, perform diagnoses, and facilitate the fabrication of printed models and retainers. This segment also provides computer-aided design and manufacturing (CAD/CAM) services, along with supplementary products like disposable covers for the scanner wand and iTero models and dies. Furthermore, it includes third-party scanners and digital scan solutions, the Invisalign Outcome Simulator (a chair-side and cloud-based application for the iTero scanner), the Invisalign Progress Assessment tool, and TimeLapse technology, which enables clinicians to compare a patient's historical 3D scans against current data. Align Technology distributes its products worldwide, with a strong presence in the United States, Switzerland, and China. Founded in 1997, the company is headquartered in Tempe, Arizona.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, Align Technology, Inc. (ALGN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 10.4% / 30% · Interest income / Revenue 0.61% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 10.4% / 33% · Receivables / Mkt Cap (36m) 10.6% / 49% · Interest income / Revenue 0.61% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 10.4% / 33.33% · Receivables / Mkt Cap (24m) 10.6% / 33.33% · Interest income / Revenue 0.61% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 0.13% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 17.3% / 33.33% · Receivables / Avg Assets (4Q) 18.2% / 33.33% · Interest income / Revenue 0.61% / 5% | Pass |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 17.6% / 33.33% · (Cash+Recv) / Total Assets 35.4% / 33.33% · Interest income / Revenue 0.61% / 5% | Fail |
It depends on the standard you follow. As of September 2026, Align Technology, Inc. (ALGN) passes 4 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global, Dow Jones and MSCI, and fails FTSE.
Yes. Align Technology, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 0.61% of each dividend: Align Technology, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.